Financial Performance - The company's revenue for Q1 2025 was ¥83,874,474.65, representing a 15.84% increase compared to ¥72,402,604.63 in the same period last year[3] - Net profit attributable to shareholders decreased by 43.56% to ¥7,208,777.38 from ¥12,771,702.45 year-on-year[3] - The basic and diluted earnings per share both fell by 43.75% to ¥0.09 from ¥0.16 in the previous year[4] - Total operating revenue for Q1 2025 reached ¥83,874,474.65, an increase of 15.5% compared to ¥72,402,604.63 in Q1 2024[17] - Net profit for Q1 2025 was ¥7,140,076.45, a decrease of 44.1% from ¥12,771,727.42 in Q1 2024[18] - Operating profit for Q1 2025 was ¥7,286,167.76, down 51.6% from ¥15,042,851.09 in Q1 2024[18] - Basic earnings per share for Q1 2025 were ¥0.09, down from ¥0.16 in Q1 2024[18] Research and Development - Research and development expenses totaled ¥8,135,185.57, an increase of 50.85% compared to ¥5,392,889.91 in the same period last year, accounting for 9.70% of revenue[4] - Research and development expenses increased to ¥8,135,185.57 in Q1 2025, compared to ¥5,392,889.91 in Q1 2024, reflecting a rise of 50.9%[17] - The company plans to continue investing in R&D and expanding its product offerings to enhance market competitiveness[6] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥2,345,166.56, an improvement from -¥3,243,303.78 in the previous year[3] - In Q1 2025, the company reported cash inflows from operating activities of CNY 36,252,366.49, an increase of 20.5% compared to CNY 30,066,938.87 in Q1 2024[19] - The net cash outflow from operating activities was CNY -2,345,166.56, improving from CNY -3,243,303.78 in the same period last year[19] - Cash outflows for purchasing goods and services decreased to CNY 13,236,374.65 from CNY 15,128,351.69, a reduction of 12.5%[19] - The company experienced a net cash outflow from investing activities of CNY -5,904,736.41, worsening from CNY -2,968,051.53 in Q1 2024[20] - The company's cash and cash equivalents at the end of Q1 2025 stood at CNY 31,730,326.97, up from CNY 30,217,615.90 at the end of Q1 2024[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,385,995,300.27, a decrease of 1.19% from ¥1,402,647,705.52 at the end of the previous year[4] - Total liabilities decreased to ¥341,698,846.15 from ¥363,298,285.26, indicating a reduction of 5.6%[15] - The equity attributable to shareholders increased slightly by 0.48% to ¥1,044,074,392.88 from ¥1,039,069,276.16 at the end of the previous year[4] - The equity attributable to shareholders of the parent company increased to ¥1,044,074,392.88 from ¥1,039,069,276.16, a growth of 0.5%[15] Shareholder Information - The total number of common shareholders at the end of the reporting period is 9,289[8] - The largest shareholder, Han Jianglong, holds 11,241,799 shares, representing 13.93% of total shares[8] - The company has approved a share repurchase plan with a total amount between RMB 25 million and RMB 50 million, with a maximum repurchase price of RMB 121.99 per share[10] - The company has repurchased a total of 94,656 shares, accounting for 0.12% of the total share capital[10] - The highest repurchase price recorded was RMB 88.99 per share, while the lowest was RMB 81.18 per share[10] - The company has not reported any changes in the participation of major shareholders in margin trading or stock lending activities[9] Financial Costs - The company reported a decrease in financial expenses, with total financial costs at ¥1,524,632.34 compared to a gain of ¥83,892.43 in Q1 2024[17]
华海诚科(688535) - 2025 Q1 - 季度财报